Study of tanruprubart for people with Guillain-Barré syndrome
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new medicine, tanruprubart (also called ANX005), for people with Guillain-Barré syndrome. It aims to see if the drug can help improve recovery when given soon after symptoms start.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Guillain-Barré syndrome by a doctor using standard guidelines.
- Your muscle weakness from GBS started within the last 10 days.
- Your weakness is severe enough that you need help walking, cannot walk, or are in the intensive care unit (disability scores 3, 4, or 5).
- You have not already received or are not planning to receive plasma exchange or IV immunoglobulin for treating this GBS episode.
- You do not have a less common GBS variant like Miller Fisher syndrome.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an experimental drug called efgartigimod (given as an infusion) can help people with Guillain-Barré syndrome recover faster. It is for adults who recently developed symptoms and have significant weakness that affects their walking.
This trial compares two blood-based treatments for Guillain-Barré syndrome: one that filters antibodies from the blood (immunoadsorption) and one that uses donated antibodies (IVIG). Both aim to reduce nerve damage and speed up recovery, and researchers want to see which works better.
This trial studies whether an inpatient rehabilitation program can help people with Guillain-Barré syndrome. It may be useful if you need structured therapy and support during recovery.
This trial tests whether noninvasive breathing support (like a mask or nasal prongs) can help people with Guillain-Barré syndrome who have trouble breathing. It aims to see if this approach can avoid the need for a breathing tube.
This trial tests whether a new medicine called imeroprubart can help people with CIDP, a nerve condition causing weakness and numbness. It may provide an alternative to current treatments like steroids or immunoglobulin therapy.
This study tests a new investigational medicine called empasiprubart when added to the standard IVIg treatment for people with Guillain-Barré syndrome. It aims to see if adding this medicine can help improve recovery compared to IVIg alone.
Hear when a new Guillain Barré Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.